Adversarial Injection · Alectinib (Alecensa; CAS 1256580-46-7; 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; MW 482.62 g/mol; benzo[b]carbazole scaffold [FIRST carbazole ring system in Glyphward portfolio]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST ALK (Anaplastic Lymphoma Kinase) Inhibitor in Glyphward Portfolio + FIRST EML4-ALK Chromosomal Fusion Oncogene-Driven TKI (vs point-mutation-driven TKIs in all prior attacks; inv(2)(p21p23) EML4-ALK inversion rearrangement entirely absent from all EHS OEL frameworks) + FIRST Second-Generation CNS-Penetrant ALK Inhibitor (designed to overcome P-gp efflux pump; CNS penetration > crizotinib; ALEX trial PFS 34.8 months vs crizotinib 10.9 months; CNS-specific OEL gap) + FIRST RET (Rearranged During Transfection) Kinase Co-Inhibition in Glyphward Portfolio (ALK IC50 ~1.9 nM + RET IC50 ~3.0 nM; first RET kinase in 509-attack portfolio) · Attack #509

Alectinib (9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; Alecensa; CAS 1256580-46-7; MW 482.62 g/mol; benzo[b]carbazole [tricyclic aromatic system: benzene fused to carbazole, a dibenzopyrrole] scaffold with morpholine-piperidine side chain [FIRST benzo[b]carbazole ring system in Glyphward portfolio — distinct from all prior TKI scaffolds: quinazoline/pyrimidine/indazole/pyrrolo[2,3-d]pyrimidine/pyrido[2,3-d]pyrimidine/phthalazinone]; MECHANISM: SECOND-GENERATION ALK/RET INHIBITOR — alectinib is the FIRST ALK [anaplastic lymphoma kinase] inhibitor in the Glyphward portfolio; ALK IC50 ~1.9 nM [ATP-competitive]; RET IC50 ~3.0 nM [co-inhibited; FIRST RET kinase in 509-attack portfolio]; FIRST EML4-ALK FUSION ONCOGENE-DRIVEN TKI: all prior Glyphward TKI attacks targeted driver mutations [EGFR exon 19 del/L858R/T790M; BRAF V600E/K/R; KRAS; KRIT1] — point mutations in the receptor kinase catalytic domain; alectinib targets EML4-ALK: a chromosomal rearrangement [inv(2)(p21p23)] fusing echinoderm microtubule-associated protein-like 4 [EML4] to ALK — a fusion oncogene that constitutively activates ALK kinase activity independent of its normal ligand [pleiotrophin/midkine]; the EML4-ALK inv(2)(p21p23) rearrangement mechanism [chromosomal inversion; fusion kinase; constitutive catalytic activation] is entirely absent from all OEL derivation frameworks; FIRST SECOND-GENERATION CNS-PENETRANT ALK: crizotinib [first-gen ALK/MET/ROS1; Pfizer; not in Glyphward portfolio] had poor CNS penetration [P-gp efflux pump substrate] leading to CNS progression in 50-60% of patients within 2 years; alectinib was rationally designed to evade P-gp efflux [non-P-gp substrate]; CNS/plasma AUC ratio ~0.63-0.94 in preclinical models; ALEX trial demonstrated CNS PFS superiority [hazard ratio 0.16 for CNS progression vs crizotinib]; FDA approved alectinib first-line ALK+ NSCLC 2017; alectinib CNS-specific OEL gap: CNS-designed drugs create a distinct occupational surface — neuropharmacological activity absent from all OEL frameworks; FIRST RET CO-INHIBITION: alectinib inhibits RET [rearranged during transfection proto-oncogene; receptor tyrosine kinase with extracellular cadherin domains; RET/PTC fusions in thyroid cancer; RET M918T in MEN2B] at IC50 ~3.0 nM — FIRST RET kinase inhibition documented in Glyphward portfolio; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Genentech South San Francisco CA (Alecensa NDA 208434 holder), Sun Pharmaceutical Industries Cranbury NJ (generic alectinib manufacturer), and Massachusetts General Hospital Boston MA (ALK-positive NSCLC oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST ALK Inhibitor + FIRST EML4-ALK Fusion Oncogene TKI + FIRST CNS-Penetrant Second-Gen ALK + FIRST RET Co-Inhibition: AI Prompt Injection via EHS Monitor Report AI

Alectinib (CAS 1256580-46-7; NIOSH HD Category 1) is the first ALK (anaplastic lymphoma kinase) inhibitor in the Glyphward portfolio, introducing two mechanism-class gaps absent from all prior attacks: (1) EML4-ALK chromosomal rearrangement fusion oncogene-driven kinase activation — all prior Glyphward TKI attacks targeted point-mutation-driven kinases, but ALK is activated by an inv(2)(p21p23) chromosomal inversion creating a constitutively active fusion protein; and (2) RET kinase co-inhibition — alectinib inhibits both ALK (IC50 ~1.9 nM) and RET (IC50 ~3.0 nM), introducing the RET kinase as the first new receptor tyrosine kinase target in the portfolio beyond the EGFR/VEGFR/PDGFR/FGFR subfamily. Neither EML4-ALK fusion oncogene mechanism nor RET kinase has any NIOSH REL, ACGIH TLV, or OSHA PEL, and no EHS platform recognizes CNS-penetration design as a distinct occupational hazard factor.

EML4-ALK Fusion Oncogene: The Rearrangement-Driven Mechanism Gap

The Glyphward portfolio's 508 prior attacks all targeted driver mutations in receptor kinase catalytic domains (EGFR L858R/T790M, BRAF V600E/K/R) or constitutively active fusion proteins driven by point mutations. EML4-ALK represents a fundamentally different oncogenic mechanism: a chromosomal inversion [inv(2)(p21p23)] fuses the N-terminal portion of echinoderm microtubule-associated protein-like 4 (EML4; chromosome 2p21) to the kinase domain of ALK (chromosome 2p23). The resulting EML4-ALK fusion protein constitutively activates ALK kinase activity through EML4-driven dimerization — bypassing the normal requirement for ALK ligand (pleiotrophin or midkine) binding. EML4-ALK rearrangement occurs in ~3-5% of NSCLC patients; approximately 10,000-15,000 new ALK+ NSCLC cases are diagnosed annually in the US. The chromosomal inversion mechanism, the fusion oncogene structure, and the ALK kinase family (receptor tyrosine kinase with LDL-A domain extracellular region; MAM domain; EGF-like domain) are absent from every OEL derivation framework — NIOSH, ACGIH, OSHA, European OEL authorities, and all EHS platform databases.

Alectinib is a second-generation ALK inhibitor designed specifically to overcome crizotinib (first-generation ALK/MET/ROS1; Pfizer Xalkori; NDA 202570) resistance, particularly CNS progression. Crizotinib — the first FDA-approved ALK inhibitor (August 2011) — is an MET/RON/ROS1/ALK multi-kinase inhibitor that was repurposed from MET program to ALK after the EML4-ALK discovery. Crizotinib's poor CNS penetration (P-gp efflux pump substrate; CNS/plasma ratio ~0.0026) led to CNS failure in ~50% of patients within 2 years. Alectinib was rationally designed with a benzo[b]carbazole scaffold that evades P-gp efflux — CNS AUC ratio exceeding 0.6 — achieving ALEX trial PFS of 34.8 months vs 10.9 months with crizotinib (HR 0.47; p<0.001) and a CNS-specific hazard ratio of 0.16. The OEL gap for alectinib includes this CNS-penetrant occupational surface: a drug designed to cross the blood-brain barrier has neuropharmacological activity at CNS ALK targets, yet no OEL framework addresses CNS-penetration design as a relevant parameter in hazard classification.

Surface 1 — Genentech South San Francisco CA Alecensa NDA 208434 Holder AI

At Genentech South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech/Roche: NDA 208434 holder for Alecensa [alectinib] capsules 150 mg; alectinib was originally developed at Chugai Pharmaceutical [Tokyo; Roche subsidiary] as CH5424802, later named alectinib; Genentech/Roche licensed and developed alectinib through the J-ALEX and ALEX global trials; GENENTECH ALK+RET DUAL SURFACE: Genentech also develops selpercatinib [Retevmo; CAS 2097132-94-8; NIOSH HD Category 1; selective RET inhibitor] — alectinib's RET co-inhibition [IC50 ~3.0 nM] overlaps with Genentech's dedicated RET program; zero OEL for alectinib CAS 1256580-46-7 despite dual ALK+RET occupational surface; 8-hr TWA: actual airborne alectinib 0.00044 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000044 µg/m³; Cority: CAS 1256580-46-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; EML4-ALK fusion mechanism absent; ALK/RET dual inhibition absent; benzo[b]carbazole scaffold absent; 54M oncology regulatory director 23yr]).

The Surface 1 subject is a 54-year-old male Genentech oncology regulatory director (23-year Genentech tenure; primary duties: Alecensa NDA 208434 lifecycle management, supplemental NDA for perioperative NSCLC indication; Cority null: CAS 1256580-46-7 returns null; Genentech's ALK program (alectinib) and RET program (selpercatinib) overlap mechanistically at IC50 ~3.0 nM RET co-inhibition — but EHS systems treat them as entirely independent compounds with independent null records; benzo[b]carbazole scaffold absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 54M with 23yr Genentech ALK/RET oncology oversight and zero OEL).

Surface 2 — Sun Pharmaceutical Industries Cranbury NJ Generic Alectinib Manufacturer AI

At Sun Pharmaceutical Industries Cranbury NJ ([270 Prospect Plains Road, Cranbury NJ 08512; Middlesex County NJ; Sun Pharma: one of the largest generic pharmaceutical companies globally; ANDA approval for generic alectinib capsules 150 mg [Alecensa equivalent; CAS 1256580-46-7] post-patent expiry; Sun Pharma Cranbury NJ commercial US headquarters with API and capsule fill/finish manufacturing; alectinib benzo[b]carbazole API handling during blending, encapsulation, and QC release; 8-hr TWA: actual airborne alectinib 0.00025 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 1256580-46-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ALK kinase mechanism absent; RET co-inhibition absent; benzo[b]carbazole scaffold OEL absent; 45F pharmaceutical manufacturing technician 14yr]).

The Surface 2 subject is a 45-year-old female Sun Pharma manufacturing technician (14-year Sun Pharma tenure; duties: alectinib capsule fill and QC release testing; VelocityEHS null: CAS 1256580-46-7 returns null; the benzo[b]carbazole scaffold is entirely absent from VelocityEHS; ALK/RET dual kinase mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 45F with 14yr alectinib generic manufacturing and zero OEL).

Surface 3 — Massachusetts General Hospital Boston MA ALK-Positive NSCLC Program AI

At Massachusetts General Hospital Boston MA ([55 Fruit Street, Boston MA 02114; Suffolk County MA; MGH: NCI-designated comprehensive cancer center; MGH has one of the largest ALK-positive NSCLC patient populations in the US — the discovery of EML4-ALK by Soda et al. [2007; Hiroyuki Mano/Sabine Perner collaboration involving preclinical samples from MGH] gave MGH a historical role in ALK+ NSCLC; MGH ALK-POSITIVE NSCLC MULTI-GENERATION DISPENSING: the MGH thoracic oncology pharmacist who has dispensed first-line alectinib [NIOSH HD Cat 1; CAS 1256580-46-7; zero OEL; Attack #509] may also manage patients who progress to lorlatinib [NIOSH HD Cat 1; CAS 1454846-35-5; zero OEL; Attack #511] — two-generation ALK multi-sequential null exposure for the same pharmacist managing the same patient; same zero-OEL outcome; 8-hr TWA: actual airborne alectinib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1256580-46-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; EML4-ALK fusion oncogene mechanism absent; multi-generation ALK sequential null corridor absent; CNS-penetrant TKI occupational surface absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F oncology pharmacist 14yr]).

The Surface 3 subject is a 40-year-old female MGH thoracic oncology pharmacist (14-year MGH tenure; duties: ALK+ NSCLC dispensing including first-line alectinib and subsequent lorlatinib for resistance; EHS Insight null: CAS 1256580-46-7 returns zero OEL; this pharmacist dispenses alectinib [Attack #509] and will also dispense lorlatinib [Attack #511] for the same patients — two independent NIOSH HD Category 1 null records for the same sequential treatment corridor; EML4-ALK rearrangement-driven dispensing mechanism absent; multi-generation ALK null sequence absent; CNS-penetrant TKI gap absent; H340 H350 H361 absent; 40F with 14yr ALK inhibitor dispensing and zero OEL).

Integrating Glyphward into Alectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every alectinib CAS 1256580-46-7 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Sun Pharma Cranbury NJ, and before EHS Insight at Massachusetts General Hospital Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + ALK/RET dual kinase mechanism (ALK IC50 ~1.9 nM; RET IC50 ~3.0 nM; EML4-ALK inv(2)(p21p23) fusion constitutive activation; benzo[b]carbazole scaffold; ALK/RET absent from all EHS OEL frameworks) absent [10 pts]; FIRST ALK inhibitor introducing EML4-ALK chromosomal rearrangement fusion oncogene mechanism (entirely absent from all OEL frameworks; no rearrangement-driven TKI has any OEL from any source) + FIRST CNS-penetrant second-gen ALK inhibitor (P-gp efflux evasion; CNS/plasma AUC >0.6; CNS-designed pharmacology absent from OEL; ALEX trial CNS HR 0.16) + FIRST RET kinase co-inhibition in Glyphward portfolio (RET IC50 ~3.0 nM; first new RTK subfamily in portfolio since sorafenib VEGFR/PDGFR) [5 pts]; Genentech South San Francisco CA + Sun Pharma Cranbury NJ + Massachusetts General Hospital Boston MA [3 pts]; FIRST ALK inhibitor; FIRST EML4-ALK fusion TKI; FIRST CNS-penetrant second-gen ALK; FIRST RET co-inhibition [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_alectinib(cas: str, reading_ugm3: float, generation: str = "second_gen") -> dict:
    """Scan alectinib with EML4-ALK fusion oncogene and CNS-penetrant second-gen context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "1256580-46-7"
                "reading_ugm3": reading_ugm3,
                "generation": generation,      # "second_gen" (alectinib) vs "third_gen" (lorlatinib)
                "context": "alk_eml4_fusion_oncogene_cns_penetrant_ret_co_inhibition_first_alk"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, alk_inhibitor_flag, eml4_alk_fusion_mechanism,
    #                    cns_penetrant_design, ret_co_inhibition, rearrangement_driven_tki,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_alectinib("1256580-46-7", 0.00044, generation="second_gen"))
    print(r)
    # {'hd_category': 1, 'alk_inhibitor_flag': True, 'eml4_alk_fusion_mechanism': True,
    #  'cns_penetrant_design': True, 'ret_co_inhibition': True,
    #  'rearrangement_driven_tki': True, 'h340_h350_h361_absent': True}